Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
